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Aim: To examine the neurocognitive outcomes in children and adolescents with
acute lymphoblastic leukemia (ALL) in remission who were treated with systemic
chemotherapy only (CTO).
Methods: Neurocognitive performances in 36 children and adolescents, aged
8.4–15.3 years, in long-term remission from ALL 4.3–12.4 years post diagnosis,
without relapse, and with no pre-diagnosis history of neurodevelopmental disorder
were compared with 36 healthy controls matched for gender, age, and parents’
socio-economic status. The former patients and the healthy controls completed an
extensive battery of standardized neuropsychological tests.
Results: Survivors who were treated by CTO obtained significantly lower scores than
did healthy controls on the domains of Copy and drawing (p = 0.001; Cohen’s d 0.85;
after controlling for Type 1 errors q = 0.006), Arithmetic (p = 0.001; Cohen’s d 0.80;
after controlling for Type 1 errors, q = 0.006), and Tactile sensory functions (p = 0.008;
Cohen’s d 0.65; after controlling for Type 1 errors, q = 0.03). Fifty percent of the ALL
group were more than 1 SD below the control groups mean on Copy and drawing. There
was an interaction between age and group (ALL vs. Control, p = 0.042) on Copy and
drawing, indicating that the youngest ALL patients exhibited the worst performance. The
oldest ALL patients performed equal to or better than the controls. A tendency in the
same direction was seen for Arithmetic and Tactile sensory functions. The ALL survivors
exhibited a steeper rising learning slope on repeated tests, with lower scores on a tactile
problem-solving task, tactile sensory tests, verbal memory, and visual attention, but they
performed as well as the controls when stimuli were repeated.
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Conclusion: The results indicate that neurocognitive long-term sequelae in ALL
survivors are limited to specific domains – particularly complex drawing, arithmetic,
and tactile processing, and novelty processing. Cognitive deficits are shown among
the youngest ALL patients. Intervention programs and school programs should account
for difficulties with processing new information and taking advantage of repetitions as a
strength, which may prevent survivors from falling behind their peers.
Keywords: acute lymphoblastic leukemia, survivors, neurocognitive, long-term sequelae, compensating
possibilities
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common
childhood malignancy, with an incidence of 3.9 per 100,000
children (Gustafsson et al., 1998; Schmiegelow et al., 2010). With
the current treatment protocols, the overall 5-year event-free
survival (EFS) over the last several decades has approached
90% in the Nordic countries (Schmiegelow et al., 2010). Central
nervous system (CNS) prophylaxis to prevent CNS relapse is
one of the major improvements in the treatment. ALL is most
typically diagnosed in preschool-age children, with a striking
incidence peak at age 2–5 years, which is a period of rapid brain
maturation and development (Krull et al., 2013).
Acute lymphoblastic leukemia, together with brain tumors,
differs from most other childhood cancers in the increased
vulnerability for attracting long-term cognitive sequelae. Cranial
radiation therapy (CRT), and CRT in combination with
chemotherapy (CT) for CNS prophylactic treatment is accepted
as a central agent for cognitive sequelae (Campbell et al., 2007).
In current treatment protocols, Intensified CT has successfully
replaced CRT without reducing the EFS (Schmiegelow et al.,
2010). Nevertheless, chemotherapy-only (CTO) protocols usually
employ simultaneous administration of different types of drugs,
including nucleoside analogs, glucocorticoids, and anti-folates,
all of which are suspected to cause both acute and delayed
neurotoxicity (Cole and Kamen, 2006).
New research has found reduced brain connectivity in ALL
patients treated with CTO, compared to healthy controls, and
it is therefore hypothesized that such changes may be associated
with the observed cognitive impairments in this group (Kesler
et al., 2014). Chemotherapy-based CNS-directed treatment may
therefore have a negative impact on neurocognitive functioning
in ALL survivors – although to a lesser extent than radiotherapy
does (Peterson et al., 2008; Jacola et al., 2016) – and has led
to an increased focus on the late effects in long-term survivors
of ALL (≥5 years after diagnosis) treated with CTO protocols
(Diller, 2011).
We performed a systematic search for studies on ALL and
neurocognitive tests in PsycInfo (OVID, 1987–2019) and Medline
(OVID, 1946–2019), using subject terms and text words. Subject
terms used in Medline were (1) Precursor Cell Lymphoblastic
Leukemia-Lymphoma/, (2) Leukemia, Lymphoid/, (3) exp
Antineoplastic Agents/, and (4) exp Neuropsychological Tests/.
The search strategy was adapted to PsycInfo and supplemented
with text word searches. In total, 72 studies were retrieved,
with 1 duplicate. Studies published between 1990 and 2019
were included. The full-search strategy can be obtained if
needed. We went through the abstracts and deleted 50 articles
that did not fit our topic. Following our inspection of the
manuscripts, articles featuring cranial radiation therapy and
those lacking healthy control groups were also excluded.
Among those articles included was one meta-analysis of
neurocognitive impairment in childhood ALL, based on 13
articles that met the criterion for inclusion (Peterson et al.,
2008). Their conclusion indicated cognitive impairment in
processing speed, verbal memory (including working memory),
some aspects of executive function (perceptual reasoning
skills), and fine motor skills among patients with ALL.
The authors state in their discussion, however, that the
neuropsychological findings were mixed with some evidence for
fine motor, executive function, and verbal memory weakness
in ALL survivors.
Turning to the findings from articles not in this meta-analysis,
Buizer et al. (2005a) found Visuomotor difficulties restricted to
the condition requiring the highest level of control, more in girls
than boys, and more in those with a short time since treatment.
In another article Buizer et al. (2005b) examined 36 ALL
patients (presumably the same ALL patients) with an attentional
test, and found that CNS-directed CTO is associated with
attentional dysfunction, particularly with intensified treatment
protocols. Oliveira-Gomes et al. (2012) concluded that ALL
children with CTO displayed mild cognitive deficits that could
limit school performance, insertion to jobs, autonomy, and life
quality. Their 20 ALL patients exhibited difficulties with executive
functions, some problem-solving strategies, self-regulation,
cognitive flexibility and inhibitory control, and recall after
interference. In a Norwegian study of long-term survivors
(Kanellopoulos et al., 2016) (ALL, n = 112 control, n = 100,
mean time 22.6 years, 7–40 years post treatment), ALL patients
had normal general intellectual ability but reduced performance
in processing speed, executive functions, and working memory
compared to peers. Another study (Kunin-Batson et al., 2014)
(ALL = 263), examining ALL patients with a mean of 9 years
from diagnosis, found mild neurocognitive difficulties, with
problems related to verbal cognitive abilities and visual-motor
integration. In a recent review, Cheung and Krull (2015)
noted that there is limited research on cognitive sequelae after
CTO treatment in ALL survivors, and that although most
such studies have described cognitive deficits in these patients,
the findings have been inconclusive. The effect of CTO on
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IQ has generally been found to be modest. Lofstad et al.
(2009) found a group difference of specific cognitive functions,
measured by the Wechsler Intelligence Scale for Children-Third
Edition (WISC-III). The deficit in the ALL group was most
striking and consistent for the verbal and attention indexes. In
addition, lower scores were revealed in complex visual-spatial
problem-solving tasks and processing speed for the survivors
of early-childhood ALL compared to the matched healthy
controls. This is in accordance with findings in a systematic
review by Cheung and Krull (2015), who revealed difficulties
in attention, processing speed, and executive functions. Others
have reported possible late effects in verbal fluency (Espy
et al., 2001) and a specific lowering of Verbal IQ (Harila
et al., 2009). Longitudinal data from childhood leukemia
survivors participating in the Childhood Cancer Survivor Study
(CCSS) supported an association between impaired intellectual
abilities on the one hand and unemployment and weaker
educational gains on the other (Krull et al., 2013). Based on
this literature, it is reasonable to conclude, as Peterson et al.
(2008) have done, that neuropsychological findings in ALL
survivors are mixed.
Changes observed in neurocognitive functions appear
to be the result of complex interactions involving genetic
predisposition, cancer type, age, and treatment modality (Ross
et al., 2004). Younger age at treatment, female gender, intrathecal
chemotherapy, and cranial irradiation are all associated with
poorer neurocognitive outcomes (Buizer et al., 2009; Kahalley
et al., 2013). Importantly, impairment in these domains can
impede the ability to learn new information and maintain
previously learned information and can lead to declines in
neurocognitive functioning (Krull et al., 2008, 2013).
In addition to the observed cognitive impairments seen
for ALL patients (Kesler et al., 2014), recent neuroimaging
studies indicate that damage to white matter are associated
with cognitive deficits in survivors of childhood cancers
(Hutchinson et al., 2017).
In sum, during the last decade there has been a growing
research focus on neurocognitive sequelae/consequences after
treatment for ALL in childhood. We wanted to extend this
research by including full neurocognitive assessments typically
used in clinical settings.
The aim of the present study is thus to examine
neuropsychological differences between survivors of childhood
ALL with no relapse, treated with CTO, compared to matched
healthy controls, using an extensive neuropsychological test
battery generating the possibility of examining if specific areas
of cognitive domains are more involved than others. We
hypothesized that there would be cognitive deficits in the ALL
group compared to the healthy control group. Based on earlier
studies, we would expect to find deficits in specific cognitive
domains, including verbal and visual-spatial deficits. In addition,
we expected difficulties with attention, working memory,
processing speed, and executive functions. Thus, the expectation
was not for an overall cognitive impairment in these patients,
but for their specific inferior cognitive performance compared to
healthy controls.
MATERIALS AND METHODS
Participants
The participants in the present study comprised 36 children
and adolescents who were long-term survivors of childhood
ALL and 36 healthy controls who were matched for age,
gender, and socio-demographic status (Table 1). The
ALL children and adolescents were recruited from Oslo
University Hospital and St. Olav’s University Hospital
in Trondheim, Norway. The ALL survivors were treated
in accordance with protocols developed in 1992, Nordic
Society of Paediatric Haematology Oncology-ALL (NOPHO-
1992) used in Denmark, Finland, Iceland, Sweden, and
Norway, without CRT.
The treatments based on the NOPHO-ALL-1992 protocol
were initiated from May 1992 through 1999, with patients
grouped as standard-risk, intermediate-risk, high-risk aged
under 5 years, high-risk 2 aged over 5 years, and very
high-risk. These treatment protocols included pulses of
high-dose methotrexate (5–8 g/m2) isolated or in combination
with high-dose cytosine arabinoside (total dose 12 g/m2)
plus multiple intrathecal injections of methotrexate as a
CNS-targeted treatment, prednisolone, doxorubicin, vincristine,
L-asparaginase, and oral 6-mercaptopurine (Gustafsson et al.,
1998). Patients were included if they met the following inclusion
criteria: 4 years or more post-diagnosis; in continuous remission
since the initial treatment, with no relapses; and completion
of a single course of treatment without CRT. A total of 51
children and adolescents from the patient pools provided by
the two hospitals met the inclusion criteria and were contacted
by regular post. Thirty-six children (70.6%), 19 girls and 17
boys, and their parents agreed to participate in the study. The
group had a mean age of 11.5 years (range 8.4–15.3 years)
and was 4.3–12.4 years post diagnosis (mean = 7.7). The
15 children who did not participate (12 girls and 3 boys)
reported difficulties in finding time for the nearly 2-day-long
evaluation period as the main reason for not participating.
Other parents declined because they did not want to remind
their children of their cancer treatment. Norway is a small
country, with a total of five University Hospitals, two of
which – Oslo University Hospital in Oslo and St. Olav’s
University Hospital in Trondheim – took part in this study.
These two university hospitals diagnosed approximately 77
of 146 children with ALL in Norway during this time span
(1989–1995). This figure amounts to 52.7% of the total sample
in Norway. There were 14 children belonging to the standard
risk group, 16 to the intermediate group, and 6 to the different
high-risk groups. To maximize the homogeneity in patient
group and exclude confounding factors, participants in the
very high-risk group treated with cranial radiation therapy or
bone-marrow transplantation and/or participants with possible
central nervous system involvement or B-cell leukemia or other
neurodevelopmental syndrome or diseases were excluded from
the study.
The physically healthy children and adolescents in
the comparison group were recruited from four public
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TABLE 1 | Sociodemographic characteristics and treatment variables in 36
children treated for ALL and 36 healthy controls.
ALL Healthy
Gender
Girls: n (%) 19 (52.7) 19 (52.7)
Age at study in years
Mean (SD) 11.5 (2.0) 11.6 (1.9)
Range 8.4–15.3 8.8–15.1
Family composition; n (%)
Both parents 27 (75.0) 27 (75.0)
Parent with partner 4 (11.1) 5 (13.9)
Parent single 5 (13.9) 4 (11.1)
Parents: age in years, mean (range)
Mother 39.6 (30− 54) 39.5 (30− 52)
Father 43.1 (32− 58) 42.6 (30− 59)
Parents: education in years, ¤, mean (range)
Mother 13.8 (10− 19) 13.8 (9− 19)
Father 14.3 (10− 20) 13.6 (9− 19)
Economy, self-evaluation; ¤
Very good; n (%) 3 (8.3) 5 (13.9)
Good; n (%) 21 (58.3) 14 (38.9)
Average; n (%) 9 (25.0) 17 (47.2)
Poor 2 (5.6) 0
Home;
Own house, n (%) 33 (91.7) 33 (91.7)
Community;
Urban, n (%) 12 (33.3) 15 (41.7)
Diagnosis and treatment
Age at diagnosis in years
Mean (SD) 3.8 (1.5)
Median 3.6
Range 1.5–7.5
Time since diagnosis in years
Mean (SD) 7.7 (1.9)
Median 7.9
Range 4.3–12.4
Treatment protocols, n (%)
Standard risk 14 (38.9)
Intermediate risk 16 (44.4)
High risk 1 4 (11.1)
High risk 2 2 (5.6)
No significant differences were seen between the groups. Missing data in the ALL
group are indicated by ¤; n = 35. We were missing data on one of the parents who
did not respond.
schools and matched by gender, age, and parents’
socioeconomic status. The schools were selected to match
demographics. As in the patient group, only pupils
from Nordic families with a Nordic first language and
without any known neurodevelopmental syndrome or
disorder were recruited. The participation rate, among
the controls was 79%, with a mean age of 11.6 years
(range 8.8–15.1 years). There was no gender difference in
participation or refusal to participate in the study. Additional
descriptions of the participants have been published elsewhere
(Lofstad et al., 2009).
Methods
Neuropsychological functions were assessed with an extensive
battery of neuropsychological tests representing a wide range of
neuropsychological functions:
A. An extended Halstead-Reitan neuropsychological
test-battery (Reitan and Wolfson, 1993), including (1),
Aphasia screening test, (2), Category Test, (3), Tactual
Performance Test, (4), Trail Making Test A and B, and (5),
Seashore Rhythm Test;
B. Matthew-Kløve Motor Steadiness Battery and
Reitan-Kløve Sensory Perceptual Examination (Reitan and
Davison, 1974), including (1), Maze Coordination, (2),
Finger and Foot Tapping, (3), Dynamometer (handgrip
strength), (4), Grooved Pegboard, (5), Tactile Form
Recognition (stereognosis), (6), Finger Agnosia, and (7),
Fingertip Writing;
C. Developmental Drawing (Yeates, 1994), including a
paper-and-pencil design-copying test;
D. Knox Cube Test (Bornstein, 1983);
E. Boston Naming Test (Baron, 2004);
F. Controlled Oral Word Association Test (COWAT FAS)
(Benton and Hamsher, 1976);
G. Children Auditory Learning Test-2 (CAVLT-2) (Talley,
1993);
H. Rey-Osterrieth Complex Figure Test (RCFT) (Meyers and
Meyers, 1995);
I. Stroop Color-word Test (Golden, 1978);
J. Paced Auditory Serial Addition Test (PASAT) (Gronwall,
1977); and
K. Conners’ Continuous Performance Test (CPT)
(Connors, 1995).
In addition, the WISC-III was used. We have previously
reported from WISC-III (Lofstad et al., 2009), but found it
useful to include this measure with the other tests used in the
assessment. In the previous publication, these results were not
converted to T-scores based on the healthy controls or included
in domain summary T-scores.
The parents were asked to complete a standardized
questionnaire regarding case history and demographic data. The
WISC-III was presented according to test protocol, beginning
with the Information subtest ending with the Mazes. The typical
neuropsychological tests were presented in a random order to
ensure that test tiredness, boredom, or other such factors would
not influence the results.
Procedure
Written permission to contact the parents of children treated for
ALL in their patient pools was provided by the Paediatric Clinics
at Rikshospitalet and St. Olav’s Hospital. Written information
about the project; parent and patient (adolescent) consensus
forms; and self-addressed, stamped envelopes were sent by
regular post to parents of the children who met the inclusion
criteria (n = 51). If forms were not returned within 3 weeks,
the parents were contacted by phone. All children whose parents
had provided informed consent were examined in a quiet room
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at the Division of Paediatric and Adolescent Medicine at the
Oslo University Hospital, Oslo, or at the Neuropsychological
Clinic at the Norwegian University of Science and Technology,
Trondheim. The WISC-III was administered on the first day,
together with interviews with the patient and parents. All
neuropsychological tests were presented on the second day in two
sessions, with a 1-hour break between sessions.
The first author, an experienced neuropsychologist (G.E.L),
administered the tests. Additional descriptions of the procedure
have been published elsewhere (Lofstad et al., 2009). To assemble
the control group, the county borough councils for schools in
one urban and one rural county were contacted to discuss the
demographics of different schools and to obtain permission to
contact school headmasters in their respective counties. Two
Trondheim city headmasters (one from an elementary school
and one from a junior high school) were contacted and asked
to create a sample of two girls and two boys in each group,
by drawing lots from gender and age-specific (according to
school year) pupil lists. The participants from these two schools
and the children from the ALL group were divided by gender,
ranged by age in months, and matched by age. The age in
months for ALL survivors without healthy matches was then
recorded, after which headmasters from the rural county of Nord-
Trøndelag were asked to select healthy matches by gender and age
in months. Headmasters sent written information and consent
forms to selected families, who were subsequently contacted by
phone. Headmasters were instructed not to include pupils with
known neurodevelopmental diseases diagnosed by the specialist
health services. Once parents and adolescents gave their informed
consent, the neurocognitive test batteries were administered in a
quiet room at their respective schools.
The Regional Committee for Medical and Health Research
Ethics – Central Norway (092-02) – approved the study.
All participants and their parents provided written informed
consent, and the research was completed in accordance with the
Declaration of Helsinki.
Statistics
The match of the two groups was evaluated by comparing the
demographical variables using Independent Sample t-tests or
Pearson χ2. The results on each neuropsychological subtest were
converted to T-scores, based on the test results from the matched
control group, thereby providing results on the same scale, which
would make it easier to see differences in performance between
the two groups on the different tests. The different test scores
were divided into separate domains, and summary T-scores was
calculated for each domain with a Mean of 50 and a SD of 10
for the control group. The neuropsychological outcome for the
ALL patients was compared to those of the healthy controls, using
Independent Sample t-test. There were some missing data in our
material in the ALL population. One WISC-III test protocol was
accidentally destroyed before it was entered into the database.
Furthermore, there were missing values on three participants
on the Connors continuous performance test (due to technical
difficulties), three on the PASAT test (tiredness and hesitation
regarding mathematical tests), two on the Stroop test, and one on
Developmental drawing. On these subjects, a mean score for the
group was inserted. Because participants were closely matched,
we followed the same procedure for control participants. On the
missing WISC-III subtests, for instance, the results for matched
controls were substituted with the groups mean score. Because
all comparisons between the two groups could result in Type
1 errors, a false discovery rate (FDR) procedure was performed
in order to control for multiple comparisons (Benjamini and
Hochberg, 1995) on the domain summary T-scores. The values
from the FDR are marked as q-values.
We also examined for differences between the ALL groups
related to treatment protocol (i.e., standard risk, intermediate
risk, and high risk).
The data were analyzed using the Statistical Package for
Social Sciences (SPSS, version 24.0, SPSS Inc., Chicago, IL,
United States). The statistical program R was used for the FDR1.
RESULTS
The demographical variables revealed no significant differences
between patients and healthy controls (see Table 1).
Neuropsychological Status
As shown in Table 2, the ALL survivors scored significantly
lower than the healthy controls on the summary scores of the
following domains: Tactile and sensory function (p = 0.008),
Abstraction and set-shifting (p = 0.045), Processing speed
(p = 0.036), Copy and drawing (p = 0.001), and Arithmetic
(p = 0.001). After controlling for multiple comparisons
differences in summary scores between the two groups, however,
ALL survivor scores were less than those of healthy controls
only for Copy and drawing, Arithmetic, and Tactile and sensory
functions (see Table 2).
When we examined Copy and drawing in greater detail to
establish how many that might have a cognitive deficit, 18 (50.0%)
of the 36 were more than 1 SD below the mean summary score of
50 (5 of the controls, 13.9%) (χ2 = 0.001). Regarding the Tactile
sensory summary score, 16 (44.4%) of 36 ALL participants were
more than 1 SD below the control groups’ mean score of 50.
Five (13.9%) of the controls had such a low score (χ2 = 0.004).
On the Arithmetic sensory summary score, 16 (44.4%) of the
ALL patients and 7 (19.4%) of the controls were more than 1
SD below the mean of 50 (χ2 of 0.02). With a more conservative
measurement regarding how many that might have a cognitive
deficit, the level of significant differences between the two groups
were the same. Sixteen (44.4%) of the 36 were more than 1 1/2
SD below the mean summary score of 50 (3 of the controls,
8.3%) (χ2 = 0.001) on Copy and drawing. On the Tactile sensory
summary score, 12 (33.3%) out of 36 ALL participants were
more than 1 1/2 SD below the control groups’ mean. Three the
controls had such a low score (χ2 = 0.009). On the Arithmetic
sensory summary score, 12 (33.3%) of the ALL patients and 4
(11.1%) of the controls were more than 1 1/2 SD below the mean
of 50 (χ2 of 0.02).
1https://www.r-project.org/
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TABLE 2 | Independent sample t-test on neuropsychological test results in 36 ALL survivors compared to 36 matched (matched for age education and socio-economic
parent status) healthy controls.
Function Patients treated for acute
lymphoblastic leukemia
Mean (SD) T-scores
Matched healthy controls
Mean (SD) T-scores
Confidence interval and
p-value, Cohen’s d; false
discovery rate, q-value for
summary scores
Motor tests
Finger tapping, dominant hand 48.9 (9.9) 50.0 (10.0) −5.8 to 3.5; p = 0.63
Finger tapping, non-dominant
hand
47.6 (9.8) 50.0 (10.0) −7.1 to 2.2; p = 0.30
Foot tapping, dominant hand 50.8 (12.2) 50.0 (10.0) −4.5 to 6.0; p = 0.77
Foot tapping, non-dominant
hand
47.0 (10.9) 50.0 (10.0) −7.9 to 1.9; p = 0.22
Grooved Pegboard dominant
hand
48.3 (14.3) 50.0 (10.0) −7.5 to 6.1; p = 0.57
Grooved Pegboard
non-dominant hand
51.5 (10.6) 50.0 (10.0) −3.3 to 6.3; p = 0.54
Kløve-Matthew, motor
steadiness:
Steadiness Maze Counter
dominant hand
44.1 (19.1) 50.0 (10.0) −13.0 to 1.3; p = 0.10
Steadiness Maze Counter
non-dominant hand
51.2 (12.7) 50.0 (10.0) −4.2 to 6.6; p = 0.65
Steadiness Maze Timer
dominant hand
44.6 (21.6) 50.0 (10.0) −13.3 to 2.5; p = 0.18
Steadiness Maze Timer
non-dominant hand
49.0 (13.5) 50.0 (10.0) −6.6 to 4.6; p = 0.72
Grip Strength dominant hand 50.2 (14.9) 50.0 (10.0) −5.8 to 6.1; p = 0.95
Grip Strength non-dominant
hand
49.9 (15.4) 50.0 (10.0) −6.2 to 6.0; p = 0.97
Summary score motor tests 48.1 (14.3) 50.0 (10.0) −7.7 to 3.9; p = 0.51
Cohen’s d 0.15; q = 0.51
Tactile sensory
Error in Tactile Form
Recognition dominant hand
41.8 (22.6) 50.1 (10.0) −16.5 to −0.1; p = 0.045
Error in Tactile Form
Recognition non-dominant
hand
45.9 (14.3) 49.9 (10.0) −9.8 to 1.8; p = 0.18
Finger-tip Number Write
dominant hand
49.2 (10.1) 50.0 (10.0) −5.5 to 3.9; p = 0.74
Finger-tip Number Write
non-dominant hand
44.8 (11.1) 50.0 (10.0) −10.1 to −0.22; p = 0.041
Summary Score Tactile
sensory
41.0 (16.8) 50.0 (10.0) −15.5 to−2.4; p = 0.008
Cohen’s d 0.65; q = 0.03
Abstraction and set shifting
Halstead-Reitan Test Battery,
(HRB), Category test
48.2 (10.3) 50.0 (10.0) −6.6 to 3.0; p = 0.46
WISC III, similarities 39.6 (11.6) 50.0 (09.9) −15.5 to −5.4; p < 0.001
Trail Making Test part B 50.3 (13.9) 50.0 (10.0) −5.4 to 6.0; p = 0.91
Summary Score Abstraction
and set shifting
44.6 (12.7) 50.0 (10.0) −10.8 to−0.01; p = 0.05
Cohen’s d 0.47; q = 0.1
Processing speed
Trail Making Test part A 49.0 (12.1) 50.0 (10.0) −6.3 to 4.2; p = 0.69
STROOP test, interference 47.3 (10.2) 50.0 (09.9) −7.4 to 2.0; p = 0.26
Tactile Form Recognition
dominant hand
42.3 (15.6) 50.0 (10.0) −13.9 to −1.5; p = 0.015
Tactile Form Recognition
non-dominant hand
45.8 (11.9) 50.0 (10.0) −9.3 to 1.0; p = 0.11
(Continued)
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TABLE 2 | Continued
Function Patients treated for acute
lymphoblastic leukemia
Mean (SD) T-scores
Matched healthy controls
Mean (SD) T-scores
Confidence interval and
p-value, Cohen’s d; false
discovery rate, q-value for
summary scores
WISC III, Digit Symbol 45.8 (12.2) 50.0 (10.0) −9.5 to 1.0; p = 0.11
WISC III, Symbol search 46.6 (11.5) 50.0 (10.0) −8.5 to 1.7; p = 0.18
Summary Score Processing
speed
44.0 (12.9) 50.0 (10.0) −11.5 to−0.6; p = 0.030
Cohen’s d 0.53; q = 0.08
Copy and drawing
Rey Complex Figure Test, copy 35.9 (23.3) 50.0 (10.0) −22.5 to −5.7; p = 0.002
Developmental Drawing 40.8 (14.8) 50.0 (09.9) −15.1 to −3.4; p = 0.003
Summary Score Copy and
drawing
35.4 (22.1) 50.0 (10.0) −22.7 to−6.5; p = 0.001
Cohen’s d 0.85; q = 0.006
Spatial tests
Tactual performance test
dominant hand
43.2 (16.0) 50.0 (10.0) −13.1 to −0.6; p = 0.03
Tactual performance test
non-dominant hand
48.5 (13.0) 50.0 (10.0) −7.0 to 3.9; p = 0.57
Tactual performance test both
hands
49.8 (11.4) 50.0 (10.0) −5.3 to 4.9; p = 0.93
WISC III Picture Completion 50.0 (12.4) 50.0 (10.0) −5.3 to 5.3; p = 1.0
WISC III Picture arrangement 45.6 (14.6) 50.0 (10.0) −10.3 to 1.5; p = 0.14
WISC Block design 41.7 (13.2) 50.0 (10.0) −13.8 to −2.3; p = 0.004
WISC III Object Assembly 40.7 (24.8) 50.0 (10.0) −18.2 to −0.41; p = 0.04
WISC III Maze 50.1 (11.7) 50.0 (10.0) −5.0 to 5.2; p = 0.96
Summary Score Spatial
tests
44.2 (15.8) 50.0 (10.0) −12.0 to 0.5; p = 0.07
Cohen’s d 0.44; q = 0.1
Verbal memory
Child Auditory Verbal Learning
Test-2 (CAVLT), immediate
recall
47.9 (8.9) 50.0 (10.0) −6.6 to 2.3; p = 0.34
CAVLT, delayed recall 47.3 (14.0) 50.0 (10.0) −8.4 to 3.1; p = 0.36
Summary Score Verbal
memory
47.1 (12.2) 50.0 (10.0) −8.2 to 2.3; p = 0.26
Cohen’s d 0.27; q = 0.29
Visual memory
RCFT immediate recall 42.9 (15.9) 50.0 (10.0) −13.4 to −0.9; p = 0.027
RCFT delayed recall 42.5 (16.1) 50.0 (10.0) −13.8 to −1.2; p = 0.021
HRB TPT-memory 54.3 (9.2) 50.0 (10.0) −0.23 to 8.8; p = 0.06
HRB TPT-localization 50.2 (10.8) 50.0 (10.0) −4.7 to 5.1; p = 0.94
Summary score Visual
memory
46.6 (14.5) 50.0 (10.0) −9.2 to 2.5; p = 0.26
Cohen’s d 0.27; q = 0.29
Verbal tests
Letter fluency, COWAT FAS 53.1 (12.7) 50.0 (10.0) −2.3 to 8.4; p = 0.26
Boston Naming Test 48.9 (13.0) 50.0 (10.0) −6.6 to 4.4; p = 0.69
WISC III Information 46.6 (13.0) 50.0 (10.0) −8.8 to 2.2; p = 0.22
WISC III Vocabulary 41.8 (15.1) 50.0 (10.0) −14.2 to −2.0; p = 0.008
WISC III Reasoning 40.0 (13.1) 50.0 (10.0) −15.4 to −4.3; p = 0.001
Summary score Verbal tests 45.1 (14.7) 50.0 (10.0) −10.8 to 1.1; p = 0.10
Cohen’s d 0.39; q = 0.16
Arithmetic
Paced Serial Addition Test
(2 × 20 item)
42.8 (16.5) 50.0 (10.0) −13.8 to −0.18; p = 0.03
Mental Calculation (3 × 17) 43.4 (12.7) 50.0 (10.0) −1.0 to −0.10; p = 0.02
WISC III Arithmetic 42.1 (9.5) 50.0 (10.0) −12.4 to −3.1; p = 0.001
(Continued)
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TABLE 2 | Continued
Function Patients treated for acute
lymphoblastic leukemia
Mean (SD) T-scores
Matched healthy controls
Mean (SD) T-scores
Confidence interval and
p-value, Cohen’s d; false
discovery rate, q-value for
summary scores
Summary Score Arithmetic 41.2 (12.0) 50.0 (10.0) −14.0 to −3.6; p = 0.001
Cohen’s d 0.80; q = 0.006
Attention
Knox cube Test 45.8 (12.7) 50.0 (10.0) −9.6 to 1.2; p = 0.13
Seashore Rhythm 49.6 (11.7) 50.0 (10.0) −5.5 to 4.7; p = 0.88
WISC III Digit Span 46.1 (8.9) 50.0 (10.0) −8.3 to 0.69; p = 0.0.09
Connors Continuous
Performance Test (CPT),
Over-all Index 46.0 (10.0) 50.0 (10.0) −8.8 to 1.1; p = 0.09
STROOP color 51.0 (10.9) 50.0 (10.0) −4.1 to 6.1; p = 0.68
STROOP word 47.0 (12.9) 50.0 (10.0) −8.6 to 2.6; p = 0.27
Summary Score Attention 46.0 (12.2) 50.0 (10.0) −9.2 to 1.3; p = 0.14
Cohen’s d 0.35; q = 0.19
The formula for computing T-score were: (((Raw score – Mean of control group)/SD of control group) ∗ 10) + 50, when a high raw score is a good performance. When a
high raw score represents a poor performance the formula is: (−((Raw score – Mean of control group)/SD of control group) ∗ 10) + 50. For the summary scores, every
T-score in the domain were used in the calculation of domain T-scores. Cohen’s d effect size: 0.20 considered small, 0.50 considered moderate, 0.80 considered large.
False discovery rate is calculated based on the 11 summary T-scores, giving a q-value. Raw scores converted to T-scores based on the healthy controls.
There were no significant differences between the groups
on the summary T-scores for the following domains: Motor
function, Spatial function, Verbal memory, Visual memory,
Verbal tests, and Attention. Individual subtests within these
domains differed between the groups, however, as can be
seen on Table 2.
Analyses of the performance/learning process and
improvement over trials in the two groups revealed that
the ALL group had a tendency to inferior scores compared
to the control group on the first presentation, but not at the
second or third trial. On TPT right hand, for instance, the ALL
group had a mean raw score on 6.72 min (SD; 3.5) vs. 5.21
(SD; 2.2) for the controls (T-score 43.2 vs. 50.0; p = 0.034). On
left hand, the raw score were 4.73 (SD; 1.4) vs. 4.40 min (SD;
1.2), (T-score 48.4 vs. 50.0, p = 0.57), and both hands 2.29 min
(SD; 1.4) vs. 2.26 (SD; 1.2) (T-score 49.8 vs. 50.0, p = 0.93). The
same tendency can also be seen in Table 2 for the Tactile Form
recognition test.
The Knox cube test was presented twice. In the first
presentation, the difference between the two groups was close
to significant (p = 0.058), with raw scores of 12.36 for the
ALL patients vs. 13.33 for the controls (T-score 44.8 [SD; 12.8]
vs. 50.0 [SD; 10.0]). The second trial yielded almost identical
results – 13.31 vs. 13.37 – which is far from significant (T-score
48.1 [SD; 11.5] vs. 50.0 [SD; 10.0], p = 0.46]). On CAVLT-
2, the ALL patients had a close to significant result on the
first recall (p = 0.072) but not on the other immediate recalls
or the delayed recall, in which the scores where more similar
(T-score ALL first, second, third, fourth and fifth trial [SD]:
45.49 [11.0], 48.87 [11.5], 52.79 [9.1], 50.94 (12.3), 49.27 [14.1]).
For the interference list and the delayed recall, the T-score
of the ALL patients T-scores were 49.4 and 47.3. Neither
score was significantly different from the control groups’ scores,
although there was a small tendency for some reduction of
the delayed score.
When comparing the different treatment protocols in the ALL
group relative to Copy and drawing, no differences could be
observed (data not shown). Nor were there observable differences
in the Arithmetic or Tactile sensory summary scores.
Gender and age (defined in months) interactions with
belonging to (ALL or Control) group were also tested. No
interaction was observed with gender, but there was an
interaction for age between group for Copy and drawing, with
the largest differences appearing in the youngest age group
(interaction treatment group and age F = 4.294, p = 0.042).
Among the oldest participants, there are no difference in
performance between ALL and control participants. Neither were
there interactions between age and gender with group for Sensory
tactile and Arithmetic area summary scores, but the findings went
in the same direction as for Copy and drawing (see Figure 1).
We also examined if there was a correlation between age and
time since diagnosis. A positive correlation was found: More time
had passed since the diagnosis for the oldest participants (Pearson
Correlation, r = 0.7).
DISCUSSION
In the present study, ALL survivors performed below the
healthy controls in 3 of the 11 summary scores examined,
after controlling for multiple comparisons. These domains were:
Copy and drawing, Arithmetic, and Tactile sensory tests. This
finding supports the hypothesis that early childhood ALL treated
with CTO influences the subsequent CNS development and is
followed by neuropsychological performance inferior to their
peers in specific neuropsychological domains. In other cognitive
domains specified in the hypothesis no differences were found.
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FIGURE 1 | Interactions between age and group (acute lymphoblastic leukemia or controls). From left: Copy and drawing; Arithmetic; Tactile sensory. Age is defined
in months. ALL, acute lymphoblastic leukemia. As can be seen from the figures, only Copy and drawing showed a significant interaction (F = 4.294, p = 0.042).
However, the tendency went in the same direction for Arithmetic, and Sensory tactile T-scores to close the gap in neuropsychological performance between ALL
patients and healthy controls with increasing age.
For Copy and drawing, the Cohen’s d showed an effect
size of 0.85, which is considered large. For the two other
domains, Arithmetic and Tactile sensory effect sizes were
0.80 and 0.65, respectively, which are considered as high
and moderate effect sizes. The mean level of difference
between the two groups was more than 1 SD for Copy
and drawing and a much higher SD (17.7 vs. 8.0) in the
ALL group than in the control group. For the two other
domains, the mean differences ware less than one 1 SD, but
the variation/dispersion was larger in the ALL group. Also,
there were significant more participants in the ALL groups
compared to controls who were more than 1 or 1 1/2 SD
below the mean summary T-score of 50 on Copy and drawing,
Tactile sensory and Arithmetic summary scores. With such
values, we consider the cognitive difficulties to be clinically
significant for the ALL group. The ALL patients demonstrated
specific difficulties, which cannot necessarily be detected without
carefully neuropsychological testing.
These findings support previous findings showing
that early childhood ALL treated with CTO influences
subsequent CNS development and is followed by inferior
neuropsychological performance compared to their peers
in specific neuropsychological domains (Liu et al., 2018).
Specifically, our results revealed that the ALL group showed
difficulties in tests measuring Copy and drawing, Arithmetic
difficulties, and difficulties with Tactile sensory functions.
Difficulties in copying and drawing/visual-spatial
constructional ability, as measured by Beery’s Developmental
Test of Visual-Motor Integration (VMI), have been documented
in other studies (Precourt et al., 2002; Kaemingk et al., 2004).
In the present study, however, the survivors scored at same
level as the controls on motor function (speed and steadiness),
which strengthens the likelihood that this finding is caused by a
difficulties in visual-spatial function, which may also be related
to mathematical thinking. Previous studies have documented a
decline in visual-spatial abilities (Performance IQ) (Montour-
Proulx et al., 2005; Jansen et al., 2006) and processing speed
(Peterson et al., 2008).
Reports of stereognostic ability and speed in tactile perception
in ALL survivors treated with CTO has to our knowledge not
been documented before.
The variation/dispersion, taken together with the mean level
of performance indicate that not all ALL patients experience
cognitive difficulties. Fifty percent or more were within 1 SD of
the mean of 50 on the three summary scores with the largest
differences between the test groups. In light of the interaction
analysis that we performed, it was clearly seen that it was the
youngest children with the shortest time since diagnosis that
showed the largest cognitive difficulties. We therefore suggest
the relatively optimistic view that with time and aging the
cognitive difficulties will be reduced. However, our study do
not have enough data to address this issue with certainty. It
could also be that there is some type of selection bias occurring
since only 70.6% of invited participants consented and took
part in the study. There should be attention given to the
fact that many studies have documented that neurocognitive
functioning has declined over time after radiation-free CTO
treatment of childhood ALL. The sample in the present study
was still in the childhood and adolescence, and may not
have grown into the typical problems regarding attention and
executive function yet, as found by previous studies focusing
on longer-term survivors (Krull et al., 2013; Cheung and Krull,
2015; Kanellopoulos et al., 2016). Our finding that the older
participants demonstrated good cognitive performance, however,
may work against the possibility that, with increasing demands
and task complexity, problems regarding attention and executive
function may arise. Liu et al. (2018) found executive function
problems to be more prevalent than attention problems in a long-
term follow-up situation, and they emphasized that survivors
should be monitored for neurocognitive problems well into long-
term survivorship, regardless of whether they showed attention
problems at the end of therapy.
Furthermore, the survivors and controls scored at a
comparable level on measures of verbal fluency, the ability
to name known objects, and motor function (both speed and
steadiness). Thus, their tendencies for lower scores on CAVLT-2
first recall and the first tactile problem solving are unlikely to be
caused by a verbal or motor function deficit.
On learning tasks, the ALL group appears to start below the
controls, catch up on repeated learning trials and showing a more
steeply rising learning slope than did the healthy controls on the
second trial the ALL patients are equal to, or, more precisely,
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are not different from the control group. Thus, the ALL group
seems to benefit from task repetition. This was seen on the Tactual
performance test and the Tactile sensory tests, with significant
differences on the first trial. On the Knox cube test, there was a
borderline significant result at the first performance (p = 0.058),
with closer to equal test results on the second trial. On the
California Verbal Learning test over 5 trials, the difference at the
first trial was close to significant (p = 0.072). Improvement came
with the second trial, and the ALL patients performed equal to
or better than (but not significantly different from) the control
group over the next trials. The tendency is small but systematic.
These findings could indicate that the ability of ALL
survivors to process and encode new information and handle
complex multifunctional tasks is impaired. The ability to
process novel stimuli is also a central contributor in the
performance of working memory tests. The steeper rising
learning slope, however, may also indicate an important
compensatory mechanism. Our findings that ALL survivors have
a tendency toward difficulties in processing novel stimuli are in
accordance with the findings of Kaemingk et al. (2004), who
observed lower scores on tests of Story Memory, and those
of Precourt et al. (2002), who reported a divergent wordlist
learning slope among ALL survivor girls compared to healthy
controls. In the latter study, the survivors who were treated
with CTO reached the same level of performance as controls
only at the fourth repetition, without a decrease in the slope.
Furthermore, Hill et al. (1997) reported deficits in visual-spatial
and verbal single-trial memory tasks: After multiple trials, the
survivors reached the same level as the controls on verbal tasks
but not on the visual-spatial task, which may indicate deficits in
learning for spatial functioning or more complex stimuli, even
after repetition.
Contrary to the common perception that cancer is related
to increased fatigue, the clinical impression was that the ALL
survivors were comparable to those of the healthy controls on
the attention domain, which includes a measure of sustained
attention, and also that the ALL survivors benefited from
repetition. It is interesting to note that the ALL survivors
performed at comparable levels to the controls on the selected
tests of attention. The finding of intact attention is somewhat
surprising and contradicts the findings of Cheung and Krull
(2015), who documented difficulties in this domain in their
systematic review.
Strengths and Limitations
Several strengths of this study are the comprehensive
neuropsychological evaluation used; the inclusion of 70.6%
of the cohort treated for childhood ALL in the two hospitals
following the inclusion criteria; the close match between ALL
survivors and the healthy control group for gender, age, and
socio-economic variables; the within-group homogeneity of the
groups; and the fact that all participants were tested by the same
experienced clinical neuropsychologist.
The findings of this study must be interpreted with some
caution, however, because the sample is relatively limited.
Furthermore, most neuropsychological tests are not pure
measures of only one specific domain. Consequently, most of the
neuropsychological tests that were included measure aspects of
several domains. For instance the Arithmetic test from WISC-III
was placed within the domain of arithmetic in this study;
but it clearly also measures aspects of working memory and
attention. Thus a low score could result from working memory
or attention problems rather than difficulties related to arithmetic
(and vice versa).
Furthermore, several of the tests on which the ALL survivors
performed poorly (WISC-III Arithmetic and Digit span and
PASAT) could also be labeled measures of working memory.
Moreover, the ALL survivors were tested at Oslo University
Hospital Rikshospitalet or at the Neuropsychological Clinic in
Trondheim, whereas the healthy children were tested at their
primary school or at the university clinic, a difference that made
it impossible for the test leader to be blinded to the subject’s
group affiliation. Altogether, these factors may limit our ability
to document smaller impairments and make generalizations
from our results.
CONCLUSION
The data in this study indicate that long-term survivors of early
childhood ALL treated with CTO suffer from neuropsychological
sequelae in copying and drawing, tactile sensory function, and
arithmetic. This study also documented a steeper learning slope
in tests of repeated trials among the ALL survivors than among
the controls. The rote memory of ALL group members for
repeated stimuli reached the same level or even slightly better
than that of the controls after repetitions, however. Thus the
changes in the learning curve documented in this study must be
examined further. There was an interaction between groups (ALL
vs. Control) and age, indicating that there is a change toward
better (i.e., good) cognitive performance in the oldest ALL group.
Intervention and school programs must account for the
deficits seen in this study. The survivors’ ability for sustained
attention and the ability to gain from repetition may serve as
an important strength and compensatory mechanism, and may
prevent survivors from falling behind their peers.
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